Establishing Reference Values for Lean Muscle Mass in the Pediatric Patient

Gregory A Metzger1, Yuri V Sebastião1, Alex C Carsel1

  • 1Center for Surgical Outcomes Research, Abigail Wexner Research Institute and the Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, OH.

Insights

This study establishes reference values for lean muscle mass in children, crucial for understanding sarcopenia

Area of Science:

  • Pediatric imaging analysis
  • Body composition assessment
  • Sarcopenia research

Background:

  • Decreased muscle mass in adults is linked to adverse outcomes.
  • The impact of sarcopenia on children is not well understood.
  • Establishing pediatric lean muscle mass norms is essential for future research.

Purpose of the Study:

  • To define reference values for lean muscle mass in healthy children.
  • To facilitate future studies on sarcopenia's effects in pediatric populations.
  • To create gender- and age-specific charts for psoas muscle area and index.

Main Methods:

  • Computed tomography (CT) scans of bilateral psoas muscles were analyzed.
  • Pearson correlation coefficients assessed relationships between muscle area and patient factors.
  • Quantile regression generated age- and sex-specific percentile curves.

Main Results:

  • Analysis included 782 children (63.1% male; median age 9.3 years).
  • Psoas muscle area showed strong correlations with age, height, and weight in both genders.
  • Gender-specific reference charts for psoas muscle area and index were developed.

Conclusions:

  • Gender-specific reference charts for pediatric psoas muscle area are now available.
  • These charts provide a baseline for assessing lean muscle mass in children.
  • This work supports future investigations into pediatric sarcopenia and its clinical impact.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
160
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
107
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
130
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
134
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
90
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
96